Current Report Filing (8-k)
December 22 2020 - 4:28PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 17, 2020
Integrity
Applications, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
0-54785
|
|
98-0668934
|
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
19
Ha’Yahalomim St., P.O. Box 12163, Ashdod, Israel
|
|
L3
7760049
|
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: 972 (8) 675-7878
N/A
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
None.
|
|
|
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§ 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
December 17, 2020, Paul V. Good PhD was appointed as a director of Integrity Applications, Inc. (the “Company”).
Mr. Goode currently serves as Vice President of Product Development at Orchestra Biomed
where he oversees development of its implantable cardiac stimulator system for hypertension. Prior to Orchestra, from 2010 until
July 2019 Paul served in several executive roles at EndoStim, including Senior Vice President of R&D, Chief Technology Officer,
and Interim CEO. In October 2019, subsequent to Mr. Goodes employment, Endostim entered into an assignment of all of its assets
for the benefit of its creditors. From 2006 through 2010 he served as VP of Research and Development at Metacure and from 2004
through 2006 Mr. Goode served as Director of Engineering at Impulse Dynamics. Prior to that, Mr. Goode was employed as Director
of Engineering at DexCom and as Senior Engineer at MiniMed. The Board has determined that Mr. Goode is an appropriate addition
to the Board as a result of his extensive experience in the medical device space.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
December 22, 2020
|
|
INTEGRITY APPLICATIONS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Jolie Kahn
|
|
|
Name:
|
Jolie Kahn
|
|
|
Title:
|
Chief Financial Officer
|